CT103A

BCMA-targeting CAR T · Nanjing IASO Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CT103A, covering 2021-11-23 to 2021-11-23. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) [Phase 1, Phase 2]

See pricing